BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Deloitte
Johnson and Johnson
Julphar
Mallinckrodt
Cerilliant
Accenture
QuintilesIMS
Dow

Generated: January 21, 2018

DrugPatentWatch Database Preview

Glatiramer acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for glatiramer acetate and what is the scope of glatiramer acetate freedom to operate?

Glatiramer acetate
is the generic ingredient in three branded drugs marketed by Teva Pharms Usa, Mylan Pharms Inc, and Sandoz Inc, and is included in four NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Glatiramer acetate has sixty-two patent family members in thirty-one countries.

There are four drug master file entries for glatiramer acetate. Three suppliers are listed for this compound.
Summary for glatiramer acetate
Medical Subject Heading (MeSH) Categories for glatiramer acetate

US Patents and Regulatory Information for glatiramer acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 091646-001 Oct 3, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Mylan Pharms Inc GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 206936-001 Oct 3, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz Inc GLATOPA glatiramer acetate INJECTABLE;SUBCUTANEOUS 090218-001 Apr 16, 2015 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for glatiramer acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for glatiramer acetate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Chubb
Fuji
Merck
Cipla
Queensland Health
Colorcon
Citi
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot